Dr. Mehling reports receiving research support from the Swiss Multiple Sclerosis Society. Dr. Johnson reports no disclosures. Dr. Antel reports having received consulting fees for serving on advisory boards, including data safety monitoring committees, from Teva, Merck-Serono, Novartis, Actelion, Biogen-Idec, GSK and Sanofi-Aventis, and has received grant support for studies related to the effects of fingolimod on the CNS from Novartis. Dr. Kappos reports receiving research support from Actelion, Advancell, Allozyne, BaroFold, Bayer Health Care Pharmaceuticals, Bayer Schering Pharma, Bayhill Therapeutics, Biogen-Idec, BioMarin, CLC Behring, Elan, Genmab, Genmark, GeNeuro SA, GlaxoSmithKline, Lilly, Merck-Serono, MediciNova, Novartis, Novo Nordisk, Peptimmune, Sanofi-Aventis, Santhera, Roche, Teva, UCB, and Wyeth. Dr. Bar-Or reports receiving personal compensation for consulting, serving on scientific advisory boards, and/or speaking activities from Bayer, Bayhill Therapeutics, Berlex, Biogen-Idec, BioMS, Diogenix, Eli-Lilly, Genentech, GSK, Guthy-Jackson/GGF, Merck-Serono, Novartis, Ono, Roche, Teva Neuroscience, and Wyeth. He has received research funding from Bayhill Therapeutics, Biogen-Idec, Genentech, and Teva Neuroscience, and has received research support from the Multiple Sclerosis Society of Canada and the Canadian Institutes of Health Research. Dr. Bar-Or has served on scientific advisory boards for the following within the past 2 years: BioMS, Diogenix, Ono Pharmacia, and Roche; and serves on the following editorial boards: Clinical & Experimental Neuroimmunology and Neurology®.